Table 1.
Characteristics and factors associated with IBTR after breast conserving surgery or mastectomy in patients in the training set (Patients diagnosed in 2000–2006)
| Univariate Analysis | Breast Conserving Surgery | Mastectomy | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients | Events | HR (95% CI) | P-value | Patients | Events | HR (95% CI) | P-value | ||
| Total | 11627 | 855 | 3497 | 273 | |||||
| Age | |||||||||
| <35 | 482 | 67 | 2.09 (1.61–2.71) | <0.0001 | 251 | 35 | 1.84 (1.25–2.70) | 0.002 | |
| 35–49 | 4007 | 341 | 1.30 (1.13–1.51) | 0.0004 | 1736 | 125 | 0.84 (0.65–1.09) | 0.19 | |
| 50–69 | 5940 | 366 | 1.00 | 1308 | 102 | 1.00 | |||
| 70+ | 1198 | 81 | 1.52 (1.20–1.94) | 0.001 | 202 | 11 | 0.86 (0.46–1.60) | 0.64 | |
| First degree family history of breast/ovarian cancer | |||||||||
| No | 7884 | 575 | 1.00 | 2443 | 172 | 1.00 | |||
| Yes | 1537 | 111 | 1.04 (0.85–1.27) | 0.72 | 386 | 34 | 1.31 (0.91–1.89) | 0.15 | |
| Histology | |||||||||
| Ductal | 9205 | 679 | 1.00 | 2733 | 225 | 1.00 | |||
| Lobular | 1101 | 106 | 1.27 (1.03–1.56) | 0.02 | 445 | 30 | 0.75 (0.51–1.10) | 0.14 | |
| Mixed | 356 | 23 | 0.93 (0.62–1.41) | 0.74 | 133 | 10 | 0.86 (0.46–1.62) | 0.64 | |
| Cribriform | 349 | 11 | 0.33 (0.18–0.59) | 0.0002 | 29 | 1 | 0.29 (0.04–2.09) | 0.22 | |
| Mucinous | 209 | 12 | 0.76 (0.43–1.35) | 0.36 | 57 | 4 | 0.73 (0.27–1.95) | 0.53 | |
| Tubular | 127 | 3 | 0.26 (0.08–0.80) | 0.02 | 18 | 2 | 1.06 (0.26–4.27) | 0.93 | |
| Apocrine | 82 | 7 | 1.42 (0.68–3.00) | 0.35 | 31 | 1 | 0.40 (0.06–2.87) | 0.36 | |
| Other | 198 | 14 | 0.87 (0.51–1.47) | 0.59 | 51 | 0 | - | ||
| pT | |||||||||
| pT1 | 8480 | 583 | 1.00 | 1137 | 76 | 1.00 | |||
| pT2 | 2979 | 254 | 1.49 (1.29–1.73) | <0.0001 | 1646 | 128 | 1.33 (1.00–1.76) | 0.05 | |
| pT3 | 80 | 6 | 1.67 (0.75–3.74) | 0.21 | 576 | 57 | 2.04 (1.44–2.87) | 0.00005 | |
| pT4 | 24 | 1 | 0.79 (0.11–5.65) | 0.82 | 102 | 10 | 2.53 (1.31–4.90) | 0.006 | |
| Positive nodes | |||||||||
| 0 | 6718 | 446 | 1.00 | 1083 | 58 | 1.00 | |||
| 1–3 | 3124 | 236 | 1.20 (1.02–1.40) | 0.03 | 1075 | 86 | 1.62 (1.16–2.25) | 0.005 | |
| 4–9 | 820 | 83 | 1.83 (1.45–2.32) | <0.0001 | 676 | 65 | 2.22 (1.56–3.17) | <0.0001 | |
| ≥10 | 515 | 42 | 1.79 (1.30–2.46) | 0.0003 | 631 | 62 | 2.76 (1.93–3.95) | <0.0001 | |
| Grade | |||||||||
| G1 | 2358 | 106 | 1.00 | 285 | 14 | 1.00 | |||
| G2 | 5017 | 357 | 1.71 (1.38–2.12) | <0.0001 | 1272 | 85 | 1.51 (0.86–2.66) | 0.15 | |
| G3 | 3285 | 302 | 2.43 (1.94–3.03) | <0.0001 | 1184 | 87 | 1.90 (1.08–3.35) | 0.03 | |
| PVI | |||||||||
| Absent | 8902 | 621 | 1.00 | 2018 | 143 | 1.00 | |||
| Present | 2714 | 233 | 1.34 (1.15–1.55) | 0.0002 | 1477 | 130 | 1.45 (1.14–1.84) | 0.002 | |
| Molecular subtype | |||||||||
| Luminal A | 4301 | 214 | 1.00 | 912 | 46 | 1.00 | |||
| Luminal B | 4652 | 366 | 1.58 (1.33–1.87) | <0.0001 | 1575 | 128 | 1.77 (1.26–2.48) | 0.001 | |
| HER-2 | 435 | 60 | 3.39 (2.55–4.52) | <0.0001 | 367 | 26 | 1.81 (1.12–2.92) | 0.02 | |
| Triple negative | 909 | 96 | 2.38 (1.87–3.03) | <0.0001 | 256 | 28 | 2.91 (1.82–4.66) | <0.0001 | |
| Hormonotherapy | |||||||||
| No | 2112 | 252 | 1.00 | 799 | 80 | 1.00 | |||
| Yes | 9314 | 600 | 0.51 (0.44–0.59) | <0.0001 | 2630 | 189 | 0.60 (0.46–0.78) | 0.0001 | |
| Chemotherapy | |||||||||
| No | 7074 | 459 | 1.00 | 1331 | 91 | 1.00 | |||
| Yes | 4422 | 395 | 1.26 (1.10–1.45) | 0.001 | 2150 | 181 | 1.30 (1.01–1.67) | 0.043 | |
| Radiotherapy | |||||||||
| None | 431 | 69 | 1.00 | 2149 | 177 | 1.00 | |||
| Intraoperative | 1635 | 184 | 0.52 (0.40–0.69) | <0.0001 | 521 | 40 | 0.82 (0.58–1.15) | 0.24 | |
| External | 9360 | 598 | 0.21 (0.17–0.27) | <0.0001 | 748 | 49 | 0.97 (0.71–1.34) | 0.87 | |
HR, hazard ratio; CI, confidence interval; PVI, peritumoral vascular invasion; Bold indicates p-values < 0.05